引言舒格利单抗是一种的全人源、全长抗程序性死亡受体配体 1（programmed cell death 1 ligand 1，PDCD1LG1，也称 PD-L1）的免疫球蛋白 G4（immunoglobulin ...

Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby ...

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...

近日，上海交通大学附属胸科医院陆舜教授团队在SCIENCE CHINA Life Sciences (《中国科学：生命科学》英文版) 发表题为“Effectiveness of PD-1/PD-L1 inhibitors in ...

通过与人类健康组织与细胞中表达的程序性死亡配体1（PD ligand 1，PD-L1）或程序性死亡配体2（PD ligand 2，PD-L2）结合，负向调节T细胞的活化与功能 ...

Ilab Co. Ltd. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer. Copyright ©2025. All ...

The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...

A woman in her 70s on pembrolizumab for non-small cell lung cancer experienced progressive fatigue, intractable nausea and reduced mobility since commencing her cancer treatment. After repeat ...

regardless of PD-L1 [PD ligand 1] expression status, leading to its approval in 2022 in China.” The characteristics of the study population were well balanced across the groups, with ...

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ®, Triclonics ® and ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.